Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Investigational Site Number : 0560001, Leuven

Memorial Sloan Kettering Cancer Center- Site Number : 8400003, New York

Investigational Site Number : 2030001, Prague

Investigational Site Number : 2030003, Prague

Investigational Site Number : 3800003, Milan

Investigational Site Number : 7240007, Madrid

Investigational Site Number : 7240001, Madrid

Investigational Site Number : 7240002, Madrid

Investigational Site Number : 2500002, Bordeaux

Investigational Site Number : 2500001, Saint-Herblain

Investigational Site Number : 2500005, Lille

Investigational Site Number : 2030002, Brno

Investigational Site Number : 2500003, Lyon

University of Colorado- Site Number : 8400005, Denver

Investigational Site Number : 2500004, Villejuif

Seattle Cancer Care Alliance- Site Number : 8400001, Seattle

Massachusetts General Hospital Site Number : 8400002, Boston

Investigational Site Number : 1240004, Edmonton

Investigational Site Number : 1240003, Vancouver

Investigational Site Number : 1240002, Toronto

Investigational Site Number : 6160004, Gdynia

Investigational Site Number : 6200001, Lisbon

Investigational Site Number : 6200002, Lisbon

Investigational Site Number : 8260003, Oxford

Investigational Site Number : 8260002, Cardiff